Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase ...

SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 ...

Sun Pharma has discontinued the development of SCD-044 after Phase 2 trials failed to meet primary goals in treating ...

Sun Pharma’s phase 2 trials of SCD-044 to treat moderate to severe psoriasis and atopic dermatitis fails to meet primary endpoint: Our Bureau, Mumbai Wednesday, June 4, 2025, 11 ...

Sun Pharma Advanced Research share price tanked 15 per centa after Vibozilimod (SCD-044) studies failed to meet the primary ...

Mumbai: Sun Pharmaceutical Industries Limited has announced the discontinuation of two clinical trials evaluating SCD-044, a ...

Sun Pharmaceutical Industries is discontinuing two trials of its drug candidate SCD-044 for moderate to severe as psoriasis ...

The shares of Sun Pharma Advanced Research Company (SPARC) fell over 18 per cent on Wednesday, on BSE, on the announcement ...

Sun Pharma Advanced Research Company (SPARC) shares plummeted nearly 20% after its psoriasis drug, SCD-044, failed to meet primary endpoints in Phase 2 trials.

Shares of Sun Pharma Advanced Research Company (SPARC), the research division of India’s largest pharmaceutical firm Sun Pharma, fell 19 per cent to Rs 158 each after unsatisfactory Phase 2 trial ...

Sun Pharma's shares experienced a 0.47 per cent decline, trading at Rs 1,659.80, alongside the sharper fall in SPARC shares ...

Shares of Sun Pharma Advanced Research Company (SPARC) shares crashed significantly on Wednesday after the company announced ...